Method for producing solid preparation for oral administration, related device and preparation
The method of spraying a liquid formulation onto a film substrate with real-time monitoring and non-destructive measurement addresses the challenge of precise dosage control in orally disintegrating films, enabling stable and customized production for individual patient needs.
Patent Information
- Application Number
- JP2024137780
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2018-10-11
- Filing Date
- 2024-08-19
- Publication Date
- 2024-11-26
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Existing methods for producing orally disintegrating pharmaceutical films struggle with controlling the precise dosage of active ingredients during industrial production, lacking non-destructive measurement and customization for individual patient needs.
A method involving spraying a liquid formulation onto a film substrate, followed by solvent evaporation, with real-time monitoring and non-destructive measurement of the active ingredient amount, allowing for customization and adjustment to achieve a predetermined dosage.
Enables stable, customized production of pharmaceutical films with precise dosages, ensuring quality and shelf-life stability of at least 6 months, suitable for individual patient needs.
Smart Images

Figure 2024164104000001_ABST
Abstract
Description
[Technical field]
[0001] The present invention relates to a method for producing a solid formulation for oral administration, the solid formulation comprising an edible substrate portion on which a first composition comprising a first medicament active ingredient is deposited, the method comprising the steps of: providing an edible substrate in the form of a film; providing a first liquid formulation comprising the first medicament active ingredient and a solvent; and then spraying the first liquid formulation onto the film and evaporating the solvent to form a first solid composition deposited on the substrate.
[0002] The present invention is particularly applicable to solid dosage forms including orally disintegrating films. [Background technology]
[0003] Oral pharmaceutical formulations of orally disintegrating films are known in particular from EP 3,281,625 and US 2017216220. Such pharmaceutical formulations are produced in particular by spreading a solution comprising a medicament active ingredient and a polymer onto a support and drying the solution so as to obtain a film.
[0004] Such an embodiment is suitable for producing large quantities of pharmaceutical agents with uniform dosages, however it may be interesting to produce a customized pharmaceutical agent of this type, for example by adapting the dosage to each patient.
[0005] For that purpose, experiments have been carried out to produce oral pharmaceutical formulations by depositing active ingredients on a substrate by inkjet printing. Such experiments are described in particular in the following documents: Sandler et al., Inkjet Printing of Drug Substances and Use of Porous Substrates-Towards Individualized Dosing Journal of Pharmaceutical Sciences 2011, Vol.100, 3396-3395; Genina et. al., Behavior of printable formulations of loperamide and caffeine on different substrates-effective print density in inkjet printing, Int.J.Pharm.2013, 453(2), 488-97; Alomari et.al., Personalized dosing: Printing a dose of one's own medicine, International Journal of Pharmaceutics 2015, 494, 568-577.
[0006] One of the technical problems associated with the industrial production of oral pharmaceutical dosage forms by printing is specifically to control the dosage of the active ingredient in each produced pharmaceutical dosage form.
[0007] The document EP 3241539 A1 illustrates this type of prior art, which does not disclose a non-destructive measurement of the amount of active ingredient, much less a comparison of this amount (which is not measured) with a reference value.
[0008] The document EP 3403643 A1 is specifically concerned with the design of compositions containing active ingredients. It discloses measurements carried out on prototypes of such compositions to verify their content. However, it does not disclose measurements that may be carried out on the active ingredients contained as a result of spraying such compositions. Summary of the Invention [Problem to be solved by the invention]
[0009] The present invention aims to enable the customized industrial production of pharmaceutical agents for oral administration. Tests performed show that the resulting drugs have a stability (i.e. shelf life) of at least 6 months. [Means for solving the problem]
[0010] The present invention involves spraying a liquid onto a surface to obtain a desired composition upon drying. It involves controlling the amount sprayed. For convenience, the expressions "predetermined amount" and "reference amount" are used synonymously to represent a target amount (amount to be obtained), and such amount is also called a "value" ("predetermined value" and "reference value" are synonymous with "predetermined amount" and "reference amount").
[0011] The present invention relates to a method of manufacture of the above-mentioned type, more particularly to a method of manufacture of a solid formulation for oral administration, said solid formulation comprising an edible substrate part on which a first composition comprising a first medicament active ingredient is deposited, said method comprising the following steps: - providing an edible substrate in the form of a film; - providing a first liquid formulation comprising a first medicament active ingredient and a solvent; and then - spraying a first liquid formulation onto the film and evaporating the solvent to form a first solid composition deposited on the substrate; The present invention relates to a method of manufacturing the same.
[0012] The method includes the following steps: - Each part is a predefined value (Q ref dividing the film into a number of portions (e.g., mechanically cut, laser cut, or otherwise cut) so as to support an amount (which may be denoted Q for a given portion) of the first active ingredient corresponding to the amount (which may be denoted Q for a given portion), i.e., adjusting the spraying according to the method so that the resulting amount Q is equal to or greater than a predetermined desired value Q ref (i.e., it is this pre-determined value Q ref (It should be "responsive" to the - after the spraying step (and according to an advantageous embodiment after drying the sprayed formulation), measuring the amount of the first active ingredient carried by each portion and comparing this measured amount with a predetermined value, said measuring not destroying the solid formulation (the skilled person can choose any conventional non-destructive measuring method from among those available, including those listed in the following description), Further includes:
[0013] The comparison allows the initiation of a treatment (or several treatments). It allows corrective measures to be taken, such as destroying a part where the amount of active ingredient is too far from a predetermined value, or spraying an additional amount on the same part if this amount is insufficient, to avoid the need to destroy it. The comparison also allows checking the spraying tuning and, if necessary, either signaling a tuning problem (for example, by initiating an alert via an audible or visual alarm or by sending an e-mail alert) or making an automatic adjustment of the tuning, or both, i.e., both signaling a tuning problem and automatically adjusting it (both alternatively and cumulatively). This comparison is performed by an electronic device, such as a processor, a microcontroller, an on-board computer, dedicated electronic components, etc.
[0014] According to another advantageous aspect of the invention, the method comprises the following features, taken alone or according to any technically possible combination: - reporting a problem with the spraying tuning when a comparison of the measured quantities with reference values reveals an abnormal deviation (this reporting is done by an electronic device such as a processor, microcontroller, on-board computer or dedicated electronic components); - adjusting the spraying tuning according to said comparison, said adjustment being performed by an electronic device such as a processor, microcontroller, on-board computer, or dedicated electronic components; - classifying the film portions into two groups by comparison with predetermined values (the method subsequently includes a sorting step for separating the two groups from each other); the first liquid formulation has a viscosity of between 2 mPa·s and 20 mPa·s and / or a surface tension of between 20 mN / m and 50 mN / m, or according to certain embodiments even between 25 mN / m and 50 mN / m; - the first active ingredient of the first liquid formulation is selected from the group consisting of an analgesic, an antihistamine, an anti-inflammatory, an antiepileptic, and a natural, synthetic, or biotechnological hormone; According to a possible embodiment, the first liquid formulation further comprises a dye; the edible substrate comprises one or more hydrolyzable polymers, preferably one or more cellulose derivatives; - spraying a first liquid formulation onto a first zone of each film portion, the method further comprising the steps of: providing a second liquid formulation comprising a second solvent, said second liquid formulation preferably comprising a second medicament active ingredient and / or a flavouring, and then spraying the second liquid formulation onto the second zone of the film and evaporating the second solvent to form a second solid composition deposited on the substrate, wherein the first and second zones of the film are separated from each other, Contains one or more of the following:
[0015] The present invention further relates to a solid formulation for oral administration obtainable by the method described above, said formulation comprising an edible substrate portion on which is deposited at least one composition comprising a medicament active ingredient.
[0016] The present invention further relates to an apparatus for the continuous production of a solid formulation for oral administration capable of implementing the method described above, comprising: a device for providing an edible substrate in the form of a film strip, the strip being configured to be divided into a plurality of portions (whether by complete or discontinuous cutting of each portion, e.g. discontinuous cutting in the form of a dotted pre-cut, to allow easy separation of such portions at a later stage); a device for printing the first liquid formulation; and an inspection device connected to the printing device, the inspection device being capable of implementing the printing of a predetermined amount of the first liquid formulation on each substrate portion; and a non-destructive measurement device for the amount of the first active ingredient carried by each portion, the inspection device comprising means for comparing the measured amount with a predetermined value of the first liquid formulation (corresponding to the predetermined amount, which is a mathematical "value" that represents a physical "amount" and implies the same reality).
[0017] According to one advantageous aspect of the invention, the manufacturing equipment further comprises an individual packaging device for each solid dosage form.
[0018] The invention will be better understood on reading the following description, given purely by way of non-limiting example and made with reference to the drawings in which: [Brief description of the drawings]
[0019] [Figure 1] FIG. 1 is a schematic diagram of a solid preparation according to the first, second, and third embodiments of the present invention. [Diagram 2] FIG. 2 is a schematic diagram of a manufacturing apparatus according to one embodiment of the present invention that enables the production of the solid dosage form of FIG. 1. [Diagram 3] FIG. 3 is a detailed view of an edible substrate that can be used with the device of FIG. 2. [Figure 4] FIG. 2 is a logic diagram showing the steps of a method for producing the solid dosage form of FIG. 1 according to one embodiment of the present invention. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0020] FIG. 1 shows a first (10), second (40), and third (60) solid dosage forms for oral administration according to the first, second, and third embodiments of the present invention, respectively.
[0021] Hereinafter, the first (10), second (40), and third (60) solid dosage forms for oral administration will be described simultaneously, and common elements will be designated by the same reference numerals.
[0022] These solid formulations are obtained by spraying. According to a possible embodiment, the spraying is driven by a spraying control which receives an input (or "tuning value" or "tuning amount").
[0023] According to a possible embodiment, the initial tuning value is set to a pre-defined value, meaning that this tuning value is equal to the pre-defined amount (value) to be sprayed at the start of the method.
[0024] According to an advantageous alternative embodiment, the initial tuning value is indexed only to this value that is predefined to represent it. In fact, it is not important to use the same numerical value for the initial tuning value and the predefined value, it only matters to be able to interpret the numerical value used as the tuning value in such a way as to enable the determination of whether the initial value corresponds to the predefined value whatever it may be, and the interpretation of subsequent values.
[0025] For example, when spraying is realized using a printing technique, the amount sprayed is determined by the spraying tuning, which according to a possible embodiment is equal to the printing resolution (which may be written as RES). For a given area to be printed, each resolution corresponds to an amount to be sprayed, and vice versa. The higher the resolution, the more dots are printed, and therefore the more amount sprayed. The printing resolution can be tuned in dots printed per unit of distance (e.g., in dots per inch, DPI), whereby the same resolution can be used in both printing directions (in the case of 2D printing). In this example, the spraying tuning is therefore the RES parameter (e.g., a resolution of 350 DPI), which corresponds to a predetermined amount to be sprayed.
[0026] In the improved version of this example, the tuning includes the number of passes NBP as an option (besides the RES resolution), so the process prints the same area NBP-1 times with the maximum resolution, then prints this same area NBP times with the RES resolution specified in the tuning to increase the maximum sprayable volume. In this case, the spraying tuning is a pair of parameters {RES, NPB} with NBP≧2 (in the case of NBP=1, which is equivalent to the example in the previous paragraph, it does not specify the number of passes and achieves only a single pass), and the pair corresponds to a pre-determined volume to be sprayed.
[0027] According to another example, the splaying tuning is the number N of bits that represent an initial predetermined value (i.e., 0 to 2 N-1 2 N The number of possible values, e.g., for N=10, there are 1024 possible values from 0 to 1023). For example, a predefined value is VP min (For example, VP min =10mg)~VP max (For example, VP max If the value of the VP is likely to vary within the range of (2N-1 ) × (VP-VP min ) / (VP max -VP min ) value. For example, using the above example values, a predetermined value of 400 mg would result in an initial spray tuning of 1023 x (400-10) / (2000-10) = 200, or 0xC8h in hexadecimal and 0x11001000b in binary. A value of N greater than 10 allows for spray tuning to be expressed with extremely fine precision. A lower N value results in less precise tuning and a higher N value results in more precise tuning.
[0028] The solid dosage form 10, 40, 60 comprises a substrate 12 and a first composition 14 deposited on the substrate. In second and third embodiments, the solid dosage form 40, 60 further comprises a second composition 16 deposited on the substrate 12.
[0029] The substrate 12 is an edible substrate and is assumed to be in the form of a film 18. Preferably, the substrate 12 is an orally disintegrating substrate. Preferably, the substrate 12 does not contain any active ingredient. Preferably, the substrate 12 has a pH adapted to the active ingredient so as to improve its preservation over time. According to a possible embodiment, the substrate 12 is obtained from one or more pH adjusting excipients such as citric acid or dilute phosphoric acid to obtain an acidic pH (as illustrated in the formulation examples below). Other excipients may be used to obtain a basic pH.
[0030] More preferably, the substrate 12 comprises one or more water-soluble polymers. Even more preferably, said water-soluble polymers are selected from among cellulose derivatives, such as hydroxypropyl cellulose (HPC), hydroxypropyl methyl cellulose (HPMC), sodium carboxymethyl cellulose (CMC-Na) or hydroxyethyl cellulose (HEC), polyvinyl derivatives, such as polyvinylpyrrolidone (PVP), polyvinyl acetate (PVA) or PVP-PVA copolymers, natural gums, such as xanthan gum or gum arabic, alginates, in particular sodium alginate, carrageenan gums, such as iota or lambda carrageenan, starches, such as corn starch, pea starch or pregelatinized starch, highly esterified pectins, type B gelatin, dextrins, pullulans.
[0031] Even more preferably, the substrate 12 comprises one or more cellulose derivatives, such as hydroxypropyl cellulose, hydroxypropyl methyl cellulose, sodium carboxymethyl cellulose, or hydroxyethyl cellulose.
[0032] Optionally, substrate 12 further comprises flavorings and / or sweeteners, either natural, such as fructose, or synthetic, such as potassium acesulfame.
[0033] Optionally, the substrate 12 contains a saliva stimulant, such as citric acid or malic acid, or talcum (Mg3SiO4O 10 (OH)2) and / or pigments such as titanium dioxide (which is not preferred due to its possible carcinogenicity).
[0034] The film 18 forming the substrate 12 preferably has a thickness of 80 μm to 500 μm, preferably 80 μm to 120 μm, but according to a possible embodiment has a thickness of 200 μm to 500 μm. According to a possible embodiment, the film 18 is designed to dissolve in the patient's mouth in less than 3 minutes, or in an advantageous embodiment in less than 30 seconds.
[0035] Substrate 12 includes first (20) and second opposing surfaces bounded by contour 22. Only the first surface 20 is visible in FIG.
[0036] The contour 22 defines a surface 24 of the substrate 12. Preferably, the surface 24 is selected to allow for oral absorption of a single dose of the solid dosage form 10, 40, 60. The surface 24 may be, for example, 0.5 cm 2 ~10cm 2 1, the contour 22 has a square shape, the sides of which are approximately 2 cm in length. Alternatively, the contour 22 may adopt other shapes, for example, a rectangle, a polygon, a circle, or an oval.
[0037] The surface 24 includes first zones 26, 46, 66 on which the first composition 14 is deposited.
[0038] The first composition 14 specifically comprises a first medicament active ingredient. The present invention is primarily concerned with relatively low concentrations of the active ingredient, such as can be achieved by spraying a small amount of the liquid composition onto a substrate. Similarly, the present invention is primarily concerned with compounds that are soluble in water or relatively non-toxic solvents. According to a possible embodiment, the first composition is limited to the first active ingredient to the exclusion of any other substances (such as excipients).
[0039] The first active ingredient may be, for example, an analgesic, an antihistamine, an anti-inflammatory, an antiepileptic, or a natural, synthetic, or biotechnological hormone.
[0040] The first active ingredient can be selected from a wide range of compounds, including both small and large molecules. Preferably, the first active ingredient is a peptide, such as desmopressin (1-desamino-8-d-arginine vasopressin).
[0041] Optionally, first composition 14 also includes a first dye, which makes its deposition on substrate 12 visible to the naked eye and allows for upstream colorimetric measurement. The first dye is selected from among food dyes, such as, for example, erythrosine or sunset yellow.
[0042] The first zones 26, 46, 66 are arranged on the first side 20 of the substrate 12. In the first and second embodiments, the first zones 26, 46 have a square or rectangular shape. In a third embodiment, the first zone 66 has a substantially ring shape, delimiting a central space 67. Other shapes for the first zones are possible, said shape corresponding, for example, to a visual drawing or a decorative pattern.
[0043] Each of the second and third solid dosage forms 40, 60 further includes a second zone 48, 68 in which the second composition 16 is deposited.
[0044] The second composition 16 may, for example, comprise a second medicament active ingredient and / or a flavoring agent, said flavoring agent being, for example, selected from among flavoring agents used in the food industry. Optionally, the second composition 16 may also comprise a second dye, thereby making its deposition on the substrate 12 visible to the naked eye.
[0045] The first (46, 66) and second (48, 68) zones are preferably separated from each other (i.e. do not overlap). More preferably, a space 30 is disposed between said first (46, 66) and second (48, 68) zones. This is advantageous in that migration of materials between different regions (which may otherwise mix together, resulting in reduced shelf life) is avoided.
[0046] According to one embodiment, as in the second formulation 40, the first (46) and second (48) zones are arranged side-by-side.
[0047] According to another alternative embodiment, the first and second zones are arranged one around the other. Specifically, in the third solid dosage form 60, the second zone 68 is arranged in a central space 67 bounded by the first zone 66.
[0048] 1, the second zones 48, 68 are located on the first side 20 of the substrate 12, similar to the first zones 46, 66. In an alternative not shown, the first and second zones are disposed on two opposing sides of the substrate 12.
[0049] The deposition of the first (14) and second (16) compositions on two zones separated from one another makes it possible to eliminate the risk of chemical interaction between said compositions, improving the stability of the solid formulation 40, 60. In an alternative not shown, the solid formulation preferably comprises at least three compositions deposited on three distinct zones of the substrate.
[0050] As described hereinafter, each of the first (14) and second (16) compositions is formed by spraying microdroplets of a solvent-containing liquid formulation onto substrate 12, followed by evaporation of said solvent. Thus, each of the first (14) and second (16) compositions contains all of the components of the corresponding liquid formulation, except for the volatile components.
[0051] According to an advantageous embodiment, the spraying is performed by a piezoelectric device. Alternatively, for example, a thermal device can be used. In the latter case, however, only active ingredients that are not decomposable by heating of the thermal device can be used, and the spraying is often less precise.
[0052] A "microdroplet" is approximately 10 -12 L~about 10 -6 By L we mean droplets having a variable size.
[0053] FIG. 2 shows an apparatus 100 that allows the production of the solid dosage forms 10, 40, 60 described above.
[0054] The apparatus 100 comprises a set of juxtaposed devices, each of said devices allowing the realization of a step of a method for the manufacture of solid dosage forms 10, 40, 60, such a method being described below.
[0055] The apparatus 10 in particular comprises a device 102 for providing a film 18, a printing device 104, a drying device 106, an analysis device 108, a sorting device 110 and a packaging device 111. According to a possible embodiment, the film 18 is obtained by hot extrusion of a polymer resin or by 3D printing. The apparatus 100 further comprises an electronic control unit 112, e.g. a computer, connected to said devices. The control unit 112 contains a program 114 making it possible to carry out the manufacturing method described below.
[0056] The providing device 102 includes a strip 120 of film 18, which is partially shown in Fig. 3. In an alternative embodiment, a device for manufacturing the film 18 is directly connected to the providing device 102. According to a possible realization of this alternative embodiment, the manufacturing device realizes the step of dividing the film 18 into a plurality of portions by producing a divided film (e.g., a pre-cut film).
[0057] The film 18 is obtained, for example, by hot extrusion of a polymeric resin or by spreading of such a resin onto a support and subsequent drying.
[0058] 2, the strip 120 is wound about itself about an axis in the form of a roller 122. Preferably, the roller 122 further comprises a support ribbon 124 that is co-wound with the strip 120. The delivery device 102 further comprises means for ejecting the strip from the roller 122.
[0059] According to an alternative not shown, the rollers are replaced by a sheet set dispensed by a loader.
[0060] The unwound strip 120 may be considered to extend primarily along a longitudinal direction X, and also along a transverse direction Y. To continue the description, the terms "inlet", "outlet", "upstream", and "downstream" with respect to the apparatus 100 extend along the longitudinal direction X.
[0061] 2 and 3, the strip 120 is pre-cut into portions 12, each portion intended to form the substrate 12 of a solid dosage form 10, 40, 60. At the start of the method, the portions 12 are secured together by the presence of a support tape 124.
[0062] 3, the portions 12 of the strip 120 are aligned along a longitudinal direction X and a lateral direction Y. Along the lateral direction, the strip 120 may include, for example, 3 to 100 aligned portions 12.
[0063] The printing device 104 includes first (130) and second (132) printing modules intended to deposit first (14) and second (16) compositions, respectively, onto the substrate 12.
[0064] Each printing module 130, 132 includes a print head 134, a reservoir 136, a pipe 138 connecting the head to the reservoir, and a pump 140 disposed in the pipe.
[0065] The reservoir 136 of each of the first (130) and second (132) printing modules contains a first (144) and second (146) liquid formulation, respectively, making it possible to obtain a first (14) and second (16) composition, respectively. Preferably, the reservoir 136 is equipped with a device for agitating the liquid formulation. Preferably, the production of the liquid formulations 144, 146 is carried out directly in the reservoir 136 immediately before the start of the printing device 104.
[0066] According to an advantageous embodiment, the first liquid formulation comprises a pH adjusting agent that improves the preservation of the active ingredient. According to a possible embodiment (which can be described as static), the pH adjusting agent is incorporated in the first liquid formulation, for example, at the time of preparation and at the latest when the reservoir is filled with the first liquid formulation. According to another embodiment (which can be described as dynamic), the pH adjusting agent is added to the liquid formulation in the reservoir 136 after a pH measurement (for example, using a pH probe in the reservoir). Depending on the result of the pH measurement, the appropriate amount of acidic or basic solution is added to correct the pH by activating the pump (or other injection device). According to a possible embodiment, the method applies a pH adjustment technique similar to any one of the following to adjust the spraying tuning (by using one or more pH thresholds that can represent a positive or negative deviation from the desired pH, each threshold being usable to start an adjustment procedure):
[0067] The printhead 134 of each of the first (130) and second (132) printing modules is capable of spraying microdroplets of a liquid formulation 144, 146 onto the film 18. The printhead 134 is preferably a thermal or piezoelectric type, more preferably a piezoelectric type printhead. Such printheads are commercially available, in particular, from Konica Minolta and Fujifilm Dimatix.
[0068] According to an alternative not shown, the printing modules each further comprise a buffer tank interposed between the pipe 138 and the print head 134. Said print head is directly connected to the buffer tank.
[0069] In addition to the above-cited components of the first (14) and second (16) compositions, the liquid formulations 144, 146 include at least one solvent and optionally an excipient.
[0070] At least one solvent of the solid formulation 10, 40, 60, liquid formulation 144, 146 intended to be prepared preferably has little or no toxicity (e.g., ICH class 3). Similarly, at least one solvent of the liquid formulation 144, 146 preferably has a low boiling point temperature so as to be easily evaporated after printing. The at least one solvent includes, for example, water and / or ethanol. Optionally, the at least one solvent further includes dimethyl sulfoxide (DMSO) for better solubilization of the compound.
[0071] Additionally, to optimize printing accuracy, it is preferable to check the viscosity and / or surface tension of the first (144) and optionally second (146) liquid formulations.
[0072] Preferably, the viscosity of the first (144) and / or second (146) liquid formulation is between 2 mPa·s and 20 mPa·s, more preferably between 2 mPa·s and 10 mPa·s. Preferably, the surface tension of the first (144) and / or second (146) liquid formulation is between 20 mN / m and 50 mN / m, according to a possible embodiment between 25 mN / m and 50 mN / m.
[0073] Sufficient viscosity and surface tension allow for the generation of stable microdroplets (ie, that do not split when sprayed by the print head 134).
[0074] As a result, the first (144) and / or second (146) liquid formulations preferably include an additive that alters its viscosity and / or its surface tension, such as propylene glycol.
[0075] Additionally, the first (144) and / or second (146) liquid formulations preferably include a pH adjuster additive selected based on the stability characteristics of the active ingredient, which can be an acidic additive, such as acetic acid, or a basic additive.
[0076] At the output of the printing device 104, the apparatus 100 comprises a conveyor 150 capable of receiving the strip of film 120 and, optionally, a rotary roller 152 for winding the support tape 124 to enable it to be separated from said strip 120. In an alternative embodiment in which the strip 120 is not pre-cut, the apparatus further comprises a device for cutting the strip between the drying device and the analysis device.
[0077] The conveyor 150 includes, for example, an endless strip 154 extending between two drive cylinders.
[0078] A drying device 106 is positioned on the path of the conveyor 150. The drying device 106 is of the oven type and includes a heating element such as an electrical resistance or an infrared element.
[0079] The analytical device 108 is also arranged on the path of the conveyor 150, downstream of the drying device 106 and above the endless strip 154. The analytical device 108 is capable of measuring the amount of the first active ingredient supported by the substrate 12 of the solid dosage form 10, 40, 60, said measurement being non-destructive to said dosage form. The analytical device 108 preferably comprises an electromagnetic spectroscopy device of the near infrared spectroscopy (NIR spectroscopy) type or of the Raman spectroscopy type, or a hyperspectral imaging device. All these devices perform non-destructive measurements, as is known, in that they simply subject the active ingredient to a spectroscopy that does not change it (in principle taking no more than a minute). Other types of measurements are also possible, for example weighing on a precision balance, a technique more commonly called PAT ("Process Analytical Technology").
[0080] These measurements, which determine the (precise) amount of active ingredient, allow the comparison of this amount with a reference value and thus the assessment of the difference between the desired amount (reference value) and the actual amount. According to an advantageous embodiment, the measurement is carried out after the liquid spray formulation has been substantially dried, so that the amount of solvent still present is as small as possible to distort the measurement. Even more advantageously, the measurement is carried out after a complete drying step. In fact, experiments have shown that the further the drying process is, the more accurate the measurement. Drying stabilizes the formulation and increases its concentration.
[0081] According to a possible embodiment, the method comprises measuring the deviation between the measured quantity and the reference value in a relative form E r Alternatively, the method may calculate this deviation in absolute form E a For example, by volume or mass, for example, in microliters (μL) or milligrams (mg), or any other suitable units.
[0082] According to a possible embodiment, the method defines an upper threshold value above which the amount of active ingredient is considered to be inaccurate. This threshold value is expressed in the relative form S r For example, percent (for example:S r = 1.5%). This threshold can alternatively be expressed in the absolute form S a For example, volume or mass (e.g.: S a = 3 μL or S a =4mg).
[0083] According to a possible embodiment, when the method determines that the difference between the amount of active ingredient measured in a given portion deviates from the reference value by more than a threshold value (e.g., a difference E of more than 1.5%) r , or a difference of more than 3 μL E a , or a difference of more than 4 mg E a), it will initiate treatment. For example, if the reference value is 400 mg and the threshold is 1.5%, the method will initiate treatment as soon as the amount exceeds 406 mg or falls below 394 mg (i.e., 1.5% above or below 400 mg). Similarly, with a threshold of 4 mg, the process will initiate treatment as soon as the amount exceeds 404 mg or falls below 396 mg.
[0084] According to a possible embodiment, this action consists in initiating a spraying adjustment action. According to a possible embodiment, the adjustment is based on a change in the resolution (for example expressed in DPI, i.e. dots per inch) of the spraying device (which may be close to inkjet printer technology). The adjustment can be made more generally by a modification of the spraying control. If the threshold is exceeded upwards, the spraying is reduced in a subsequent stage of the series (i.e. in a subsequent part - not in the part that was the subject of the measurement that initiated the adjustment action). Similarly, if the threshold is exceeded downwards, the spraying is increased in a subsequent stage of the series.
[0085] According to another possible embodiment (where the threshold may be greater than the exemplary values given above, e.g., S r =10%), this treatment relies on sorting the portions that caused the inaccurate measurement. This sorting relies, for example, on transferring the portions with the inaccurate measurement to a receptacle that can be discarded (destroyed) when full. Alternatively, if a portion contains an insufficient amount of active ingredient, instead of discarding the portion, the method can reroute it through the spraying step again, thereby supplementing the amount of active ingredient to approach the reference value.
[0086] According to another possible embodiment, this action relies on signaling the presence of a deviation via an electronic warning device (e.g. triggering the illumination of a red LED, the display of a message in the form of a text or a pictogram, the generation of an alarm sound, the sending of an automatic e-mail, etc.). According to a possible embodiment, the alarm is continuously triggered as long as the measured value does not return within the range defined by the threshold value. This alarm can be cumulative with the sorting action (and updated spraying, if necessary) and also with the spraying adjustment action.
[0087] According to a possible embodiment, the method defines several thresholds at which different treatments are initiated depending on the threshold crossed. According to a possible embodiment, the process includes a low threshold at which a first treatment is initiated and a high threshold at which a second treatment is initiated. These thresholds can be relative or absolute. For example, a relative low threshold is 1.5% and a relative high threshold is 10%, or an absolute low threshold is 4 mg and an absolute high threshold is 20 mg. The selection of the thresholds can depend on the active ingredient and on the individualization parameters (age, sex, height, weight, medical history, etc.). This selection can be made by a pharmacy competent person, thus resulting in the definition of different thresholds for each of many possible configurations. According to a possible embodiment, the method is then set to automatically select the relevant thresholds thus defined according to the input data (active ingredient, age, sex, height, weight, medical history, etc.). According to a possible embodiment, the method includes a means for manually inputting the thresholds, the latter replacing the automatic selection (if the latter is realized) and thus the operation is stopped by the manual input.
[0088] According to a possible embodiment, the first action is a signaling action (alarm) for exceeding a low threshold. According to a possible embodiment, the first action is a spraying adjustment action (already explained). According to a possible embodiment, exceeding a lower limit initiates the two above mentioned actions (reporting and spraying adjustment).
[0089] According to a possible embodiment, the second action is a warning (alarm) action signaling that a high threshold has been exceeded, which may be different from the warning (alarm) action signaling that a low threshold has been exceeded (to indicate an increased importance of the alarm). According to a possible embodiment, the second action is a sorting action, optionally including additional spraying (already explained). According to a possible embodiment, exceeding the high threshold initiates the two above mentioned actions (reporting and sorting + possibly additional spraying).
[0090] According to one variant, the method defines different upper and lower thresholds (in practice, overdosing and underdosing of a drug do not necessarily have the same result). Therefore, according to a possible embodiment, the method defines a lower upper threshold and a higher upper threshold, as well as a lower and a higher lower threshold. Each of these thresholds can be relative or absolute.
[0091] According to a possible embodiment, it is the same action initiated when the lower limit threshold is exceeded and when the lower upper threshold is exceeded, but according to a variant, they are different actions, for example the alarms can be different so that the operator is informed in which direction the threshold is exceeded, or in yet another variant the adjustments can be different (for example faster in case of an overdose than in case of an underdose or vice versa).
[0092] According to a possible embodiment, the same action is initiated when the high lower threshold is exceeded and when the high upper threshold is exceeded, but according to a variant, these are different actions, for example the alarms can be different so that the operator is informed in which direction the threshold is exceeded, or in yet another variant, the sorting can be different as already mentioned (which can result in the discarding of the overdosed portion, while an attempt is made to "fix" the underdosed portion rather than discarding it).
[0093] According to a possible embodiment, the method continuously realises the adjustment action of the spraying tuning without checking if the threshold is exceeded. For example, the method realises a feedback loop, whereby the percentage of the difference between the measured amount and the reference value is subtracted from the spraying tuning value applied as an input parameter to the subsequent spraying command (and the resulting corrected spraying tuning is applied to the spraying command). This percentage can take various values. The higher the percentage, the faster the correction, but the greater the risk of overcorrection (and thus generating deviations in the other direction). The lower the percentage, the slower the adjustment, but the less likely it is to generate parasitic oscillations. For example, if the spraying tuning is (at least initially) equal to the reference value, if the percentage is set to 30%, if the reference value is set to 200 mg and the measured amount is 210 mg, the deviation Ea is 10 mg. The method then sends an instruction to the sprayer to spray 3 mg less (10 mg -30%). In the next iteration, if the measured amount (e.g. 207 mg) still exceeds the reference value (in the given example, Ea=7 mg), the method instructs the sprayer to spray 2.1 mg less (-30% of 7 mg). In this way, the method updates the spraying tuning value during the iteration so that the measured value (after spraying) is closer to the reference value. If the spraying tuning value is not equal to the reference value (at the beginning of the process) but is only representative of it (e.g. if this tuning value is the DPI print resolution), the method adjusts the tuning value (according to possible implementations) proportionally to the deviation found. For example, if the measured value is 10% below the reference value and the percentage applied for the adjustment is 30% (as above), the tuning value is increased by 30% of 11.11%, or 3.33% (note that a value 10% below the normal value must be increased by 11.11% to return to the normal value). For tuning values that do not vary linearly compared to the measured quantity, appropriate non-linear adjustments can be applied (ie, different from the proportional adjustments discussed above).
[0094] According to another possible embodiment, the adjustment action of the spraying tuning is only initiated when the response exceeds a threshold value. In this case, the measured quantity must be sufficiently different from a predetermined value for the adjustment to be initiated. This adjustment can be a feedback loop as described in the previous paragraph. However, it can also be another type of correction. For example, each time the threshold is evaluated to be exceeded, the method can adjust the spraying command by a constant value below the threshold (i.e. not a percentage of deviation). In practice, it is certain that the deviation is above this constant value.
[0095] In a simplified implementation, no adjustments are made to the spraying commands: adjustments are made only once at the start of each production run, in which case the comparison of the measured quantities to the reference values is not used to initiate adjustments (but is used to initiate other actions, such as sorting of parts).
[0096] A sorting device 110 is also arranged downstream of the analysis device 108 on the path of the conveyor 150. The sorting device 110 is capable of removing from the conveyor those solid dosage forms 10, 40, 60 that do not have a satisfactory analysis result. The sorting device 110 comprises, for example, a nozzle 156 that blows compressed air or aspirates the defective solid dosage forms 10, 40, 60 in order to remove them from the conveyor 150. Such a sorting is advantageous because it allows a comprehensive control of the production. Any product resulting from the method is of the correct quality (as it has been checked). This makes it possible to directly release the final product at the end of the manufacturing process and distribute it to patients (i.e. without the need to implement additional quality procedures).
[0097] The packaging device 111 is arranged at the output position of the conveyor 150. Upstream of the packaging device, two rollers 160 are arranged, each capable of discharging a sheet of packaging material 162 of the aluminum sheet type covered with a plastic film. The packaging device 111 comprises drive means capable of placing the sheet of packaging material 162 in contact with each of the faces of the solid dosage forms 10, 40, 60.
[0098] Preferably, the packaging device 111 includes a laser etching or printer type writing device 164 capable of writing information onto the packaging material 162 as it scrolls.
[0099] Downstream of the rollers 160, the packaging device 111 comprises a sealing device 166 capable of bonding two sheets of packaging material 162 together so as to form a closed compartment 170 around each of the solid dosage forms 10, 40, 60. The sealing device 166 comprises, for example, a heating element. Preferably, the sealing device 166 also comprises means for achieving sealing under a controlled atmosphere of the nitrogen type.
[0100] Downstream of the sealing device 166, the packaging device 111 comprises a cutting device 168 capable of separating the closed compartments 170 containing the solid dosage forms 10, 40, 60 from one another.
[0101] A description will now be given of a method 200 for manufacturing the solid dosage forms 10, 40, 60. The method is illustrated by a logic chart in FIG.
[0102] Initially (step 202), a pre-cut strip 120 of film 18 arranged on a support tape 124 is presented to the inlet of the printing device 104 and moves along the longitudinal direction X. The print head 134 of the first printing module 130 deposits microdroplets of a first liquid formulation 144 on the first side 20 of each portion 12 of the strip 120 (step 204). The deposition takes place on the first zones 26, 46, 66 of each portion 12. The amount of first liquid formulation 144 per portion 12 is controlled by the program 114 as a function of the amount of the first active ingredient desired (reference amount) for the solid dosage form 10, 40, 60 to be manufactured. The apparatus 100 is calibrated, for example, by assaying the first liquid formulation 144 with the first active ingredient before implementing the manufacturing method.
[0103] For the second and third embodiments, the print head 134 of the second printing module 132 then deposits (step 206) microdroplets of a second liquid formulation 146 onto the second zones 48, 68 of each portion 12 of the strip 120. The amount of second liquid formulation 146 per portion 12 is controlled by the program 114.
[0104] At the exit of the printing device 104, the support tape 124 is wound on a rotary roller 152 and separated from the strip 120 of film 18. A portion 12 of said strip 120 is received on a conveyor 150 and driven to the drying device 106. The solvent of the first (144) and second (146) liquid formulations finishes evaporating (step 208) resulting in the first (14) and second (16) compositions deposited on the substrate 12. The solid formulations 10, 40, 60 described above are thus obtained.
[0105] The solid dosage forms 10, 40, 60 are then driven by a conveyor to an analytical device 108. For each solid dosage form 10, 40, 60, the analytical device measures (step 210) the amount Q of the first active ingredient deposited on the substrate 12. The measurement is performed, for example, by near-infrared spectroscopy or Raman spectroscopy.
[0106] The program 114 compares each measured value Q with a reference value Q stored in the program. ref For example, the program 114 compares the value Q with [Q ref ±Δ Q ] is checked to see if it is within the range of Q is also a value stored in the program (corresponding to a single threshold). According to a possible embodiment, the program 114 adjusts the spraying tuning to the Q value (this is symbolized in FIG. 4 by the arrow inclined from step 212 to the spraying step 204). According to a possible embodiment, the program ...corresponding to a single threshold). Q Larger than Q ref The spraying tuning is adjusted (whether upwards or downwards) only if it deviates from . According to one variant, one (or more) specific thresholds are used. According to another variant, the adjustment is systematic (regardless of the value of Q and thus independent of any thresholds).
[0107] The program 114 identifies each solid dosage form 10, 40, 60 belonging to the first or second group whose value Q falls within or falls outside the target range, respectively. The sorting device 110 removes the dosage forms belonging to the second group from the conveyor 150 (step 214).
[0108] Therefore, all solid dosage forms 10, 40, 60 remaining on the conveyor 150 downstream of the sorting device 110 are within the range [Q ref ±Δ Q ] includes an amount Q of a first active ingredient contained within the
[0109] If second composition 16 includes a second active ingredient, the analysis and sorting steps are also performed on said second active ingredient (step 216).
[0110] Each solid dosage form 10, 40, 60 is then individually packaged by packaging device 111 (step 218). On each package, writing device 164 writes information such as a lot number, an identifier for the first and / or second active ingredients, or a manufacturing date or expiration date.
[0111] As such, the individually packaged solid dosage forms 10 , 40 , 60 are collected at the output of the device 100 .
[0112] Optionally, the method further comprises a secondary packaging step in which the individually packaged solid dosage forms, 10, 40, 60, are grouped together in a cardboard box-type container.
[0113] The above described apparatus 100 and method 200 allow significant flexibility in the manufacture of solid dosage forms 10, 40, 60. The program 114 allows for adjusting, modifying and monitoring in real time the amount of the first (144) and / or second (146) liquid formulation sprayed onto each portion 12 of the strip 120. This facilitates the sequential production of solid dosage forms 10, 40, 60 corresponding to different dosage amounts without interrupting production.
[0114] Similarly, the liquid formulations 144, 146 in the printing device 104 can be rapidly modified to continuously produce solid formulations containing different active ingredients from the same substrate.
[0115] Thus, the device 100 and method 200 allow for easy and low-cost production of pharmaceutical drugs by tailoring the dose to each patient.
[0116] In the embodiment described above, the strip 120 is provided pre-cut before the printing step 204. In an alternative not shown, the provided strip 120 is continuous and the method comprises a step of cutting said strip into portions 12 after the printing step. Preferably, said cutting step is performed before the analysis steps 210, 212 and the sorting step 214.
[0117] According to an alternative embodiment, the solid dosage form 10, 40, 60 is not intended to be used as an orally disintegrating formulation, but in the form of a buccal patch, which may or may not be mucoadhesive. To produce this alternative, only the properties of the substrate 12 must be modified.
[0118] The embodiments described for the implementation of the method may be transferred to the corresponding embodiments relating to the manufacturing apparatus and vice versa. EXAMPLES
[0119] Example embodiment 1.- Production of the film 18 on the substrate 12 The goal is to obtain a flexible, non-brittle substrate 12 that has a slightly acidic pH (4.7-5.0), has a low humidity level, specifically less than 10%, and dissolves in less than 10 s. Four formulations were developed:
[0120] → Formulation 1: - Hypromellose - Vegetable glycerin - Purified water - Dilute Phosphoric Acid R
[0121] → Formulation 2: - Pullalane - Microcrystalline Cellulose - Corn starch - Polysorbate 80 - Vegetable glycerin - Purified water - Dilute phosphoric acid - Titanium(IV) oxide
[0122] → Formulation 3: - HPMC (Hydroxypropyl methylcellulose) - Citric Acid - Kollicoat® (Sigma-Aldrich)
[0123] → Formulation 4: - HPMC - Citric Acid - Kollicoat® - Moisture retarders, such as EPO (Poly(butyl methacrylate-co-(2-demethylaminoethyl) methacrylate-co-methyl methacrylate) 1:2:1)
[0124] Preferably, the cellulose derivative represents at least 40 wt% of the dry composition and the acid is preferably used in a proportion of less than 1%.
[0125] The formulation is spread onto a flat surface and dried. A film 18 is obtained with a thickness of about 250 μm. Alternatively, it can be obtained with a smaller thickness, for example, 100 μm or 120 μm.
[0126] 2.- Preparation of the first liquid formulation 144 - Active ingredient (desmopressin)-40mg / ml - DMSO:Ethanol (50:50) - Propylene glycol 30% - Acetic acid 1% - Pigment (e.g. Sunset Yellow) - 5mg / ml
[0127] The present invention may be configured as follows. (Section A1) A method (200) for producing a solid formulation (10, 40, 60) for oral administration, the solid formulation comprising an edible substrate portion (12) having a first composition (14) deposited thereon, the first composition comprising a first medicament active ingredient; The method comprises the steps of: - providing (202) said edible substrate in the form of a film (18); - providing a first liquid formulation (144) comprising said first pharma- ceutical active ingredient and a solvent; and then - spraying (204) the first liquid formulation onto the film and evaporating the solvent to form the first solid composition (14) deposited on the substrate; Including, The method comprises the steps of: - Each part is a predefined value (Q ref dividing the film (18) into a plurality of portions (12) so as to support an amount (Q) of a first active ingredient corresponding to - measuring (210) the amount of the first active ingredient supported by each portion after said spraying step and comparing (212) it with said predetermined value, said measuring not destroying said solid dosage form; A manufacturing method comprising the steps of: (Section A2) The manufacturing method described in paragraph A1, further comprising a step of reporting a problem with spraying tuning when a comparison of the measured amount with the predetermined value reveals an abnormal deviation. (Section A3) The method according to paragraph A1 or A2, further comprising adjusting the spraying tuning according to the comparison. (Section A4) The method for producing a film according to any one of paragraphs A1 to A3, further comprising a step of classifying the film portions (12) into two groups taking into account a step (212) of comparing the measured amount of a first active ingredient with the predetermined value, the method then comprising a sorting step (214) in which the two groups are separated from each other. (Section A5) The manufacturing method according to any one of items A1 to A4, wherein the first liquid preparation (144) has a viscosity of 2 Pa·s to 20 Pa·s and / or a surface tension of 25 mN / m to 50 mN / m. (Section A6) The method according to any one of paragraphs A1 to A5, wherein the first active ingredient of the first liquid formulation (144) is selected from the group consisting of an analgesic, an antihistamine, an anti-inflammatory, an antiepileptic, and a natural, synthetic, or biotechnological hormone. (Section A7) The method according to any one of items A1 to A6, wherein the first liquid preparation (144) further comprises a dye. (Section A8) The method according to any one of items A1 to A7, wherein the first liquid preparation (144) further comprises a pH adjuster. (Section A9) The method according to any one of items A1 to A8, wherein the edible substrate (12) comprises one or more hydrolyzable polymers, preferably one or more cellulose derivatives. (Section A10) The method according to any one of items A1 to A9, wherein the edible base material (12) contains a moisture-proofing agent. (Section A11) The method according to any one of paragraphs A1 to A10, wherein the pH of the edible substrate (12) is adapted to the active ingredient. (Section A12) spraying said first liquid formulation (144) onto a first zone (46, 66) of each film portion (12), said method comprising the steps of: - providing a second liquid formulation (146) comprising a second solvent, said second liquid formulation preferably comprising a second medicament active ingredient and / or a flavouring agent, and then - spraying the second liquid formulation onto a second zone (48, 68) of the film and evaporating the second solvent to form a second solid composition (16) deposited on the substrate, the first and second zones of the film are separated from one another; The method for producing the solid preparation (40, 60) according to any one of items A1 to A11, further comprising: (Section A13) A solid formulation for oral administration (10, 40, 60) obtained by the method according to any one of paragraphs A1 to A12, the solid formulation comprising an edible substrate portion (12) on which at least one composition (14) containing a medicament active ingredient is deposited. A solid formulation for oral administration (10, 40, 60). (Section A14) A continuous production apparatus (100) for a solid preparation for oral administration (10, 40, 60) capable of implementing the method according to any one of items A1 to A12, comprising: - a device (102) for providing said edible substrate in the form of a strip (120) of film (18), said strip being adapted to be divided into a plurality of portions (12); - a device (104) for printing said first liquid formulation (144); - an inspection device (112, 114) connected to said printing device, said inspection device being capable of printing a predetermined amount of a first liquid formulation (144) onto each substrate portion (12); - a device for non-destructive measurement (108) of the amount (Q) of the first active ingredient carried by each portion; Including, The testing device converts the measured quantity (Q) into a predetermined value (Q ref ). (Section A15) The manufacturing apparatus according to item A14, further comprising an individual packaging device (111) for each solid dosage form (10, 40, 60).
[0128] The present invention may also be configured as follows. (Section B1) A method (200) for producing a solid formulation (10, 40, 60) for oral administration, the solid formulation comprising an edible substrate portion (12) having a first composition (14) deposited thereon, the first composition comprising a first medicament active ingredient; The method comprises the steps of: - providing (202) said edible substrate in the form of a film (18); - providing a first liquid formulation (144) comprising said first pharma- ceutical active ingredient and a solvent; and then - spraying (204) the first liquid formulation onto the film and evaporating the solvent to form the first solid composition (14) deposited on the substrate; Including, The method comprises the steps of: - dividing said film (18) into a plurality of portions (12) such that each portion carries an amount (Q) of a first active ingredient corresponding to a predetermined value (Qref); - measuring (210) the amount of the first active ingredient supported by each portion after said spraying step and comparing (212) it with said predetermined value, said measuring not destroying said solid dosage form; A manufacturing method comprising the steps of: (Section B2) The manufacturing method described in paragraph B1, further comprising a step of reporting a problem with spraying tuning when a comparison of the measured amount with the predetermined value reveals an abnormal deviation. (Section B3) The method according to paragraph B1 or B2, further comprising adjusting the spraying tuning according to the comparison. (Section B4) The method according to any one of paragraphs B1 to B3, further comprising a step of classifying the film portions (12) into two groups taking into account a step (212) of comparing the measured amount of a first active ingredient with the predetermined value, the method then comprising a sorting step (214) in which the two groups are separated from each other. (Section B5) The manufacturing method according to any one of items B1 to B4, wherein the first liquid preparation (144) has a viscosity of 2 Pa·s to 20 Pa·s and / or a surface tension of 25 mN / m to 50 mN / m. (Section B6) The method according to any one of paragraphs B1 to B5, wherein the first active ingredient of the first liquid formulation (144) is selected from the group consisting of an analgesic, an antihistamine, an anti-inflammatory, an antiepileptic, and a natural, synthetic, or biotechnological hormone. (Section B7) The method according to any one of items B1 to B6, wherein the first liquid preparation (144) further comprises a dye. (Section B8) The method according to any one of items B1 to B7, wherein the first liquid preparation (144) further comprises a pH adjuster. (Section B9) The method according to any one of items B1 to B8, wherein the edible substrate (12) contains one or more hydrolyzable polymers. (Section B10) The method according to any one of items B1 to B9, wherein the edible base material (12) contains a moisture-proofing agent. (Section B11) The method according to any one of paragraphs B1 to B10, wherein the pH of the edible substrate (12) is adapted to the active ingredient. (Section B12) spraying said first liquid formulation (144) onto a first zone (46, 66) of each film portion (12), said method comprising the steps of: - providing a second liquid formulation (146) comprising a second solvent, and then - spraying the second liquid formulation onto a second zone (48, 68) of the film and evaporating the second solvent to form a second solid composition (16) deposited on the substrate, the first and second zones of the film are separated from one another; The method for producing the solid preparation (40, 60) according to any one of items B1 to B11, further comprising: (Section B13) The method according to paragraph B12, wherein the second liquid formulation comprises a second pharma- ceutical active ingredient and / or a flavoring agent. (Section B14) A continuous manufacturing apparatus (100) for a solid preparation for oral administration (10, 40, 60) capable of implementing the method according to any one of items B1 to B13, comprising: - a device (102) for providing said edible substrate in the form of a strip (120) of film (18), said strip being adapted to be divided into a plurality of portions (12); - a device (104) for printing said first liquid formulation (144); - an inspection device (112, 114) connected to said printing device, said inspection device being capable of printing a predetermined amount of a first liquid formulation (144) onto each substrate portion (12); - a device for non-destructive measurement (108) of the amount (Q) of the first active ingredient carried by each portion; Including, A continuous manufacturing apparatus (100), wherein the inspection device comprises means (114) for comparing the measured quantity (Q) with a predetermined value (Qref) corresponding to a predetermined amount of the first liquid formulation. (Section B15) The manufacturing apparatus according to item B14, further comprising an individual packaging device (111) for each solid dosage form (10, 40, 60).
Claims
1. A method (200) for producing a solid formulation (10, 40, 60) for oral administration, the solid formulation comprising an edible substrate portion (12) on which a first composition (14) comprising a first medicament active ingredient is deposited, The method comprises the steps of: - providing (202) said edible substrate in the form of a film (18); providing a first liquid formulation (144) comprising said first medicament active ingredient and a solvent, and then - spraying (204) the first liquid formulation onto the film and evaporating the solvent to form the first solid composition (14) deposited on the substrate; Including, The method comprises the steps of: - Each part has a predetermined value (Q ref dividing said film (18) into a plurality of portions (12) so as to support an amount (Q) of a first active ingredient corresponding to - measuring (210) the amount of the first active ingredient carried by each portion after said spraying step and comparing (212) it with said predetermined value, said measuring not destroying said solid dosage form; A manufacturing method comprising the steps of:
2. The method of claim 1 further comprising the step of reporting a problem with spraying tuning when a comparison of the measured quantity to the predetermined value reveals an abnormal deviation.
3. The method of claim 1 or 2, further comprising adjusting the spraying tuning according to the comparison.
4. 4. The method according to claim 1, further comprising a step of classifying the film portions (12) into two groups taking into account a step of comparing (212) the measured amount of a first active ingredient with the predetermined value, the method then comprising a sorting step (214) in which the two groups are separated from each other.
5. The method according to any one of claims 1 to 4, wherein the first liquid formulation (144) has a viscosity of between 2 Pa·s and 20 Pa·s and / or a surface tension of between 25 mN / m and 50 mN / m.
6. 6. The method of claim 1, wherein the first active ingredient of the first liquid formulation (144) is selected from the group consisting of analgesics, antihistamines, anti-inflammatory agents, anti-epileptic agents, and natural, synthetic, or biotechnological hormones.
7. The method of any one of claims 1 to 6, wherein the first liquid formulation (144) further comprises a dye.
8. The method of any one of claims 1 to 7, wherein the first liquid formulation (144) further comprises a pH adjuster.
9. A process according to any one of claims 1 to 8, wherein the edible substrate (12) comprises one or more hydrolysable polymers, preferably one or more cellulose derivatives.
10. The method of any one of claims 1 to 9, wherein the edible substrate (12) comprises a moisture barrier.
11. The method according to any one of claims 1 to 10, wherein the pH of the edible substrate (12) is adapted to the active ingredient.
12. spraying said first liquid formulation (144) onto a first zone (46, 66) of each film portion (12), said method comprising the steps of: - providing a second liquid formulation (146) comprising a second solvent, said second liquid formulation preferably comprising a second medicament active ingredient and / or a flavouring agent, and then - spraying said second liquid formulation onto a second zone (48, 68) of said film and evaporating said second solvent to form a second solid composition (16) deposited on said substrate, the first and second zones of the film are separated from one another; A method for producing the solid formulation (40, 60) according to any one of claims 1 to 11, further comprising:
13. A solid formulation (10, 40, 60) for oral administration obtained by the method according to any one of claims 1 to 12, said solid formulation comprising an edible substrate part (12) on which is deposited at least one composition (14) comprising a medicament active ingredient.
14. An apparatus (100) for the continuous manufacture of a solid formulation for oral administration (10, 40, 60) capable of implementing the method according to any one of claims 1 to 12, said apparatus comprising: a device (102) for providing said edible substrate in the form of a strip (120) of film (18), said strip being adapted to be divided into a plurality of portions (12); - a device (104) for printing said first liquid formulation (144); an inspection device (112, 114) connected to said printing device, said inspection device being capable of achieving the printing of a predetermined amount of a first liquid formulation (144) onto each substrate portion (12); - a device for the non-destructive measurement (108) of the amount (Q) of the first active ingredient carried by each portion; Including, The testing device converts the measured quantity (Q) into a predetermined value (Q ref . The continuous manufacturing apparatus (100) comprising a means (114) for comparing the
15. 15. The manufacturing apparatus of claim 14, further comprising an individual packaging device (111) for each solid dosage form (10, 40, 60).
Citation Information
Patent Citations
Forming apparatus for solid medicine unit
JP1977076419A
Medication dispensing device and method
JP2005517593A
Thin films exhibiting non-self-aggregating and uniform hybridization, and drug delivery systems made therefrom
JP2006516634A
Multi-row multi-drug intraoral dissolving film manufacturing device and manufacturing method
JP2017505642A
